title: Plasma and epithelial lining fluid pharmacokinetics of ceftolozane and tazobactam alone and in combination in mice.
abstract: Ceftolozane is a new cephalosporin with activity against Gram-negative and Gram-positive microorganisms. However, the compound is susceptible to degradation by extended-spectrum beta-lactamases (ESBLs). Tazobactam is an ESBL inhibitor and is combined with ceftolozane to broaden its activity. Surprisingly, although tazobactam has been available for over 20 years, few if any reliable data exist on the tazobactam pharmacokinetic (PK) properties in mice. To evaluate the PK and pharmacodynamic (PD) relationships in mice, the PK properties of tazobactam and ceftolozane were extensively investigated. Thigh-infected neutropenic CD-1 mice were injected intraperitoneally with a single 0.1-ml dose containing ceftolozane, tazobactam, or both compounds. Ceftolozane was applied in 2-fold-increasing doses of 4 mg/kg of body weight to 64 mg/kg alone or in combination. Tazobactam was combined in reverse doses (thus, 64/4 mg/kg, 32/8 mg/kg, etc.) (n = 2 per time point). In separate validation experiments, ceftolozane-tazobactam was given alone or in combination at 32/8 mg/kg and 8/32 mg/kg (n = 4 per time point). Plasma samples (one per mouse) and bronchoalveolar lavage samples were collected at up to 12 time points until 6 h after administration. There were no significant differences in the ceftolozane and tazobactam PK alone versus combined, indicating no PK interaction. The PKs were linear and dose proportional for both compounds and showed a good penetration in the epithelial lining fluid. The estimated mean (standard deviation) half-life of ceftolozane was 0.287 h (0.031 h), and that of tazobactam was 0.176 h (0.026), and the V was 0.43 liter/kg and 1.14 liter/kg, respectively. The estimates of tazobactam parameters can also be used to (re)interpret PD data.
authors.affiliation: Radboudumc, Nijmegen, The Netherlands.
authors.forename: M J
authors.initials: MJ
authors.lastname: Melchers
authors.affiliation: Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.
authors.forename: E
authors.initials: E
authors.lastname: Mavridou
authors.affiliation: Radboudumc, Nijmegen, The Netherlands Erasmus MC, Rotterdam, The Netherlands.
authors.forename: S
authors.identifier: http://orcid.org/0000-0002-6194-7447
authors.initials: S
authors.lastname: Seyedmousavi
authors.affiliation: Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.
authors.forename: A C
authors.initials: AC
authors.lastname: van Mil
authors.affiliation: Radboudumc, Nijmegen, The Netherlands.
authors.forename: C
authors.initials: C
authors.lastname: Lagarde
authors.affiliation: Radboudumc, Nijmegen, The Netherlands Erasmus MC, Rotterdam, The Netherlands jwmouton@gmail.com.
authors.forename: J W
authors.initials: JW
authors.lastname: Mouton
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002511:Cephalosporins / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D004926:Escherichia coli / Q000472:pathogenicity; D005260:Female; D007711:Klebsiella pneumoniae / Q000472:pathogenicity; D051379:Mice; D010397:Penicillanic Acid / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use; D011485:Protein Binding; D000078142:Tazobactam; D013848:Thigh / Q000382:microbiology / Q000473:pathology
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; C519491:ceftolozane; D010397:Penicillanic Acid; D000078142:Tazobactam
references.citation: J Antimicrob Chemother. 2012 Oct;67(10):2463-9
references.pmid: 22773741
references.citation: J Antimicrob Chemother. 2013 Jan;68(1):177-83
references.pmid: 22941899
references.citation: Antimicrob Agents Chemother. 2013 Apr;57(4):1577-82
references.pmid: 23274659
references.citation: Antimicrob Agents Chemother. 2013 Dec;57(12):6305-10
references.pmid: 24100499
references.citation: Antimicrob Agents Chemother. 2014;58(2):1218-23
references.pmid: 24277025
references.citation: Antimicrob Agents Chemother. 2014 May;58(5):2964-7
references.pmid: 24566183
references.citation: Int J Antimicrob Agents. 2014 Jun;43(6):533-9
references.pmid: 24856078
references.citation: J Infect. 2014 Sep;69(3):266-77
references.pmid: 24780763
references.citation: Int J Antimicrob Agents. 2014 Sep;44(3):218-21
references.pmid: 25108877
references.citation: J Antimicrob Chemother. 2014 Oct;69(10):2713-22
references.pmid: 24917579
references.citation: Antimicrob Agents Chemother. 2015 Apr;59(4):2299-304
references.pmid: 25645843
references.citation: Antimicrob Agents Chemother. 1996 Feb;40(2):325-30
references.pmid: 8834874
references.citation: BMC Infect Dis. 2006;6:55
references.pmid: 16545113
references.citation: J Antimicrob Chemother. 2008 Feb;61(2):235-7
references.pmid: 18065413
references.citation: Antimicrob Agents Chemother. 2012 Jan;56(1):258-70
references.pmid: 22024819
references.citation: Antimicrob Agents Chemother. 2012 Jan;56(1):544-9
references.pmid: 22064538
references.citation: Antimicrob Agents Chemother. 2012 Jun;56(6):3086-91
references.pmid: 22450972